Article Text

Download PDFPDF
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead
  1. Rui Providência1,2,
  2. Jean-Paul Albenque1,
  3. Eloi Marijon3,4,
  4. Serge Boveda1
  1. 1 Département de Rythmologie, Clinique Pasteur, Toulouse, France
  2. 2 Faculty of Medicine, University of Coimbra, Coimbra, Portugal
  3. 3 Heart Institute, Cedars Sinai Medical Center, Los Angeles, USA
  4. 4 Paris Cardiovascular Research Center, Paris, France
  1. Correspondence to Dr Rui Providência, Département de Rythmologie, Clinique Pasteur, 45 avenue de Lombez, BP 27617, 31076 Toulouse Cedex 3, France; rui_providencia{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Authors' reply We have read with interest the comments by Bin Abdulhak and colleagues1 to our recently published article.2 We share the same opinion concerning the use of dabigatran in this setting. Thus, in our article we have proposed the same posology in face of the similar findings: despite the lack of conclusive evidence in support of any particular dabigatran dosage or timing for interrupting or restarting drug therapy, like Bin Abdulhak and colleagues,1 …

View Full Text


  • Contributors RP has prepared the response to the letter which was revised and completed with suggestions of the three remaining authors. All authors approved the final version.

  • Competing interests RP has received honoraria for serving as a speaker and consultant for Boheringher-Ingelheim and as a co-investigator in the ENGAGE-AF TIMI 48 trial. There are no conflicts of interest by other coauthors.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles